Cover Image
市場調查報告書

促血紅細胞生長素產生催化劑:治療應用和全球市場

Erythropoietin Stimulating Agents: Therapeutic Applications and Global Markets

出版商 BCC Research 商品編碼 346499
出版日期 內容資訊 英文 164 Pages
訂單完成後即時交付
價格
Back to Top
促血紅細胞生長素產生催化劑:治療應用和全球市場 Erythropoietin Stimulating Agents: Therapeutic Applications and Global Markets
出版日期: 2016年01月01日 內容資訊: 英文 164 Pages
簡介

全球促血紅細胞生長素產生催化劑 (ESA) 市場,預計從2015年到2020年以0.2%的年複合成長率發展,市場規模從2015年的72億美元擴大到2020年的約73億美元。

本報告提供全球促血紅細胞生長素產生催化劑 (ESA) 市場相關調查、全球市場及治療應用概要、美國&世界市場趨勢分析與年複合成長率預測、促血紅細胞生長素的主要類型、主要地區、各應用領域四個市場規模分析、癌症治療/慢性肝疾病 (CKD) 治療/HIV治療/貧血治療的應用範圍分析、市場&供應商形勢的影響的主要趨勢與課題、產業的發展和影響市場的生技仿製藥的來到,及主要企業簡介等彙整,為您概述為以下內容。

第1章 簡介

第2章 摘要

第3章 概要

  • 定義
  • 製劑的促血紅細胞生長素
  • 促血紅細胞生長素的開發階段
  • 促血紅細胞生長素的應用
  • 促血紅細胞生長素的副作用
  • 製造手法的優點及缺點

第4章 R&D製劑的開發平台

第5章 全球促血紅細胞生長素製劑市場預測

  • 全球促血紅細胞生長素製劑市場預測: 各類別
  • 全球促血紅細胞生長素製劑市場預測: 各類型
  • 全球促血紅細胞生長素生技藥品市場預測: 各類型
  • 全球促血紅細胞生長素生技仿製藥製劑市場預測: 各類型
  • 全球促血紅細胞生長素製劑市場預測: 各應用領域
  • 全球促血紅細胞生長素製劑市場預測: 各地區
  • 全球促血紅細胞生長素製劑市場預測: 各地區
  • 全球促血紅細胞生長素生技藥品市場預測: 各地區
  • 全球促血紅細胞生長素生技仿製藥製劑市場預測: 各地區
  • 全球促血紅細胞生長素製劑市場預測: 各應用領域
  • 全球促血紅細胞生長素製劑市場預測: 各應用領域
  • 全球促血紅細胞生長素生技仿製藥製劑市場預測: 各應用領域
  • 全球紅血球產生素Alpha製劑市場預測: 各地區
  • 全球紅血球產生素β製劑市場預測: 各地區
  • 全球促血紅細胞生長素生物仿製藥製劑市場預測: 各地區
  • 全球及其他的促血紅細胞生長素生技藥品市場預測:各地區
  • 全球肝疾病取向促血紅細胞生長素製劑市場預測:各地區
  • 全球癌症疾病取向促血紅細胞生長素製劑市場預測:各地區
  • 全球及其他疾病取向促血紅細胞生長素製劑市場預測:各地區
  • 全球紅血球產生素Alpha製劑市場預測: 各應用領域
  • 全球紅血球產生素β製劑市場預測: 各應用領域
  • 全球Epoetin alfa製劑市場預測 各應用領域
  • 全球及其他的促血紅細胞生長素生技藥品市場預測: 各應用領域
  • 全球市場的預測 EPOGEN 製劑:各地區
  • 全球市場的預測 EPOGEN 製劑:各應用領域
  • 全球市場的預測 PROCRIT 製劑:各地區
  • 全球市場的預測 PROCRIT 製劑:各應用領域
  • 全球市場的預測 EPREX 製劑:各地區
  • 全球市場的預測 EPREX 製劑:各應用領域
  • 全球市場的預測 ARANESP 製劑:各地區
  • 全球市場的預測 ARANESP 製劑:各應用領域
  • 全球市場的預測 NEORECORMON 製劑:各地區
  • 全球市場的預測 NEORECORMON 製劑:各應用領域
  • 全球市場的預測 MIRCERA 製劑:各地區
  • 全球市場的預測 MIRCERA 各應用領域

第6章 促進要素、課題

  • 慢性肝疾病的案例增加
  • 癌症盛行率的增加
  • 血栓症及眼球充血球癆 (PRCA) 的風險
  • 學名藥競爭加劇

第7章 業者情勢、企業簡介

  • 3SBIO INC.
  • AMEGA BIOTECH
  • AMGEN INC.
  • BIOCON
  • BIOSIDUS
  • BLAUSIEGEL
  • CELON LABS
  • CENTER OF MOLECULAR IMMUNOLOGY
  • CHALVER LABORATORIES
  • CJ HEALTHCARE
  • CLARIS LIFESCIENCES
  • DR. REDDY'S LABORATORIES.
  • EMCURE PHARMACEUTICALS
  • HINDUSTAN ANTIBIOTICS
  • HOSPIRA INC.
  • JCR PHARMACEUTICALS CO. LTD.
  • JOHNSON & JOHNSON
  • LANDSTEINER SCIENTIFIC S.A. DE C.V.
  • LA RENON HEALTHCARE
  • LG LIFE SCIENCES
  • LUPIN LTD.
  • MEDICE DRUG PUTTER GMBH & CO. KG
  • NOVARTIS INTERNATIONAL AG
  • PANACEA BIOTEC
  • PROBIOMED
  • RELIANCE LIFE SCIENCES
  • ROCHE
  • RPG LIFE SCIENCES
  • SERUM INSTITUTE OF INDIA
  • SHANGHAI CHEMO WANBANG BIOPHARMA CO. LTD.
  • SHANTHA BIOTECHNICS
  • STADA ARZNEIMITTEL AG
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • VHB LIFE SCIENCES LTD.
  • WOCKHARDT LIMITED
  • ZUVENTUS HEALTH CARE
  • ZYDUS CADILA HEALTHCARE

圖表

目錄
Product Code: PHM130A

The global market for erythropoietin stimulating agents (ESAs) will grow from nearly $7.2 billion in 2015 to nearly $7.3 billion by 2020 with a compound annual growth rate (CAGR) of 0.2% for the period 2015-2020.

This report provides:

  • An overview of the global markets and therapeutic applications for erythropoietin stimulating agents (ESAs).
  • Analyses of U.S. as well as international market trends, with data from 2014, 2015, and projections of compound annual growth rates (CAGRs) through 2020.
  • Coverage of the market in value terms broken down by major types of erythropoietin, by major regions, and by applications.
  • Coverage of applications including cancer therapy, chronic kidney disease (CKD) therapy, HIV therapy, and anemia therapy.
  • Major trends and challenges affecting the market and the supplier landscape.
  • A look at industrial developments and the advent of biosimilars impacting the market.
  • Analysis of the risks associated with the market for abusive uses of ESAa and their adverse effects.
  • Profiles of major players in the industry.

image1

REPORT SCOPE

SCOPE OF REPORT

The scope of this report is broad and covers erythropoietin drug used globally in various types of applications. The market is broken down in terms of the various types of erythropoietin drug by region and by applications. Revenue forecasts from 2015 to 2020 are given for erythropoietin drug, with its applications and regional markets.

The report also includes a discussion of the major players in each of the regional markets for erythropoietin drug. It explains the major market drivers of the global erythropoietin drug industry, the current trends within the industry, major industry challenges and the regional dynamics of the global erythropoietin drug market. The report concludes with a special focus on the supplier landscape. It includes detailed profiles of the major vendors in the erythropoietin drug industry globally.

ANALYSTS' CREDENTIALS

This report has been developed by the market research analysts at Bizimpact Knowledge Services LLP, a market research and services company. The project has been managed by Aneesh Kumar, a partner in the company, along with input from various subject-matter experts. Aneesh Kumar has more than seven years experience in handling various custom research projects and has worked with a multinational company on various research assignments on global markets.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • INFORMATION SOURCES
  • RESEARCH METHODOLOGY
  • ANALYSTS' CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, 2014-2020 ($ MILLIONS)

CHAPTER 3 OVERVIEW

  • DEFINITION
  • ERYTHROPOIETIN AS A DRUG
  • DEVELOPMENTAL STAGES OF ERYTHROPOIETIN
  • APPLICATIONS OF ERYTHROPOIETIN
  • SIDE EFFECTS OF ERYTHROPOIETIN
    • CARDIOVASCULAR
    • HEMATOLOGIC
    • CENTRAL NERVOUS SYSTEM
    • PSYCHIATRIC
    • ONCOLOGIC
    • GASTROINTESTINAL
    • DERMATOLOGIC
  • PROS AND CONS OF MANUFACTURING METHODS:
    • PROS
    • CONS

CHAPTER 4 R&D DRUG PIPELINE

  • TABLE 1 MAJOR EPO R &D DRUG PIPELINE BY TRIAL PHASE

CHAPTER 5 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUG

  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY CATEGORY
  • TABLE 2 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY CATEGORY, THROUGH 2020 ($ MILLIONS)
  • FIGURE 1 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY CATEGORY, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY TYPE
  • TABLE 3 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • FIGURE 2 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY TYPE, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE
  • TABLE 4 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • FIGURE 3 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE
  • TABLE 5 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION
  • TABLE 6 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 5 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION
  • TABLE 7 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 6 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION
    • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUG MARKET BY REGION
    • TABLE 8 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 7 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)
    • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION
    • TABLE 9 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 8 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION
    • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY APPLICATION
    • TABLE 10 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 9 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)
    • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION
    • TABLE 11 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
    • FIGURE 10 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOETIN-ALFA DRUGS BY REGION
  • TABLE 12 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 11 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOETIN-BETA DRUGS BY REGION
  • TABLE 13 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 12 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION
  • TABLE 14 GLOBAL MARKET FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 13 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR OTHER ERYTHROPOIETINBIOLOGIC DRUGS BY REGION
  • TABLE 15 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 14 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION
  • TABLE 16 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 15 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY DISEASES BY REGION
  • TABLE 17 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS ONCOLOGY DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 16 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY DISEASES BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION
  • TABLE 18 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 17 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOETIN-ALFA DRUGS BY APPLICATION
  • TABLE 19 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 18 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOETIN-BETA DRUGS BY APPLICATION
  • TABLE 20 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 19 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR DARBEPOETIN-ALFA BY APPLICATION
  • TABLE 21 GLOBAL MARKET FOR DARBEPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 20 GLOBAL MARKET SHARE FOR DARBEPPOIETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION
  • TABLE 22 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 21 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOGEN DRUGS BY REGION
  • TABLE 23 GLOBAL MARKET FOR EPOGEN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 22 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPOGEN DRUGS BY APPLICATION
  • TABLE 24 GLOBAL MARKET FOR EPOGEN DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 23 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR PROCRIT DRUGS BY REGION
  • TABLE 25 GLOBAL MARKET FOR PROCRIT DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 24 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR PROCRIT DRUGS BY APPLICATION
  • TABLE 26 GLOBAL MARKET FOR PROCRIT DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 25 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPREX DRUGS BY REGION
  • TABLE 27 GLOBAL MARKET FOR EPREX DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 26 GLOBAL MARKET SHARE FOR EPREX DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR EPREX DRUGS BY APPLICATION
  • TABLE 28 GLOBAL MARKET FOR EPREX DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 27 GLOBAL MARKET SHARE FOR EPREX DRUGS BY APPLICATION, 2015 AND 2020 (%) 7
  • GLOBAL MARKET FORECAST FOR ARANESP DRUGS BY REGION
  • TABLE 29 GLOBAL MARKET FOR ARANESP DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 28 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR ARANESP DRUGS BY APPLICATION
  • TABLE 30 GLOBAL MARKET FOR ARANESP DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 29 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR NEORECORMON DRUGS BY REGION
  • TABLE 31 GLOBAL MARKET FOR NEORECORMON DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 30 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR NEORECORMON DRUGS BY APPLICATION
  • TABLE 32 GLOBAL MARKET FOR NEORECORMON DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 31 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR MIRCERA DRUGS BY REGION
  • TABLE 33 GLOBAL MARKET FOR MIRCERA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 32 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY REGION, 2015 AND 2020 (%)
  • GLOBAL MARKET FORECAST FOR MIRCERA BY APPLICATION
  • TABLE 34 GLOBAL MARKET FOR MIRCERA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • FIGURE 33 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY APPLICATION, 2015 AND 2020 (%)

CHAPTER 6 DRIVERS AND CHALLENGES

  • INCREASING CASES OF CHRONIC KIDNEY DISEASE
    • DIABETES
    • FIGURE 34 NUMBER OF PEOPLE AGES 20 TO 79 WITH DIABETES, BY REGION, 2013 AND 2035 (MILLIONS)
    • FIGURE 35 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES BY TOP TEN COUNTRIES, 2013 (MILLIONS)
    • FIGURE 36 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES, BY TOP TEN COUNTRIES, 2035 (MILLIONS)
    • FIGURE 37 NUMBER OF AMERICANS DIAGNOSED WITH DIABETES, 2009-2013 (MILLIONS)
    • HYPERTENSION
    • FIGURE 38 PREVALENCE OF HYPERTENSION IN PEOPLE AGED ABOVE 25 YEARS BY REGION, 2008 AND 2014
    • TABLE 35 GLOBAL PREVALENCE OF HYPERTENSION BY REGION, 2000-2025 (MILLIONS)
    • TABLE 36 U.S. INCIDENT OF ESRD BASED ON DISEASES, 2011 AND 2012 (MILLIONS)
    • TABLE 37 GLOBAL POPULATION OVER THE AGE OF 60, THROUGH 2020 (MILLIONS)
    • TABLE 38 U.S. INCIDENT OF ESRD BASED ON ETHNICITY, 2011 AND 2012 (MILLIONS)
  • INCREASING PREVALENCE OF CANCER
  • FIGURE 39 GLOBAL CANCER PREVALENCE BY TYPE, 2012 (%)
  • FIGURE 40 GLOBAL CANCER PREVALENCE BASED ON FIVE YEAR PERIOD BY TYPE, 2008-2012 (%) 15
  • FIGURE 41 CANCER PREVALENCE IN MORE DEVELOPED REGIONS BY TYPE, 2012 (%)
  • FIGURE 42 CANCER PREVALENCE BASED ON FIVE YEAR PERIOD IN MORE DEVELOPED REGIONS BY TYPE, 2008-2012 (%)
  • FIGURE 43 CANCER PREVALENCE IN LESS DEVELOPED REGIONS BY TYPE, 2012 (%)
  • FIGURE 44 CANCER PREVALENCE BASED ON FIVE-YEAR PERIOD IN LESS DEVELOPED REGIONS BY TYPE, 2008-2012 (%)
  • TABLE 39 INCIDENCE OF ANEMIA BY CHEMOTHERAPY AGENTS
  • RISK OF THROMBOSIS AND PURE RED CELL APLASIA (PRCA)
    • CARDIOVASCULAR PROBLEMS
    • THROMBOSIS IN CANCER PATIENTS
    • INCREASED TUMOR PROGRESSION
    • ZIVODUINE TREATED HIV INFECTED PATIENTS
    • PURE RED CELL APLASIA
  • INCREASING GENERIC COMPETITION
    • SYNTHETIC ERYTHROPOIETIN
    • TRANSFORMING GROWTH FACTOR BETA SUPERFAMILY

CHAPTER 7 VENDOR LANDSCAPE AND COMPANY PROFILES

  • TABLE 40 GLOBAL ERYTHROPOIETIN BIOLOGIC DRUGS MARKET SHARE BY MANUFACTURER, 2014 (%/$ MILLIONS)
  • 3SBIO INC.
  • TABLE 41 3SBIO'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • AMEGA BIOTECH
  • AMGEN INC.
  • TABLE 42 AMGEN'S ERYTHROPOETIN DRUGS PIPELINE
  • TABLE 43 AMGEN'S ERYTHROPOETIN DRUGS PATENTS
  • TABLE 44 ARANESP'S SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 45 EPOGEN'S SALES BY REGION, 2011-2014 ($ MILLIONS)
  • TABLE 46 AMGEN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 45 AMGEN'S REVENUE BY REGION, 2014 (%)
  • FIGURE 46 AMGEN'S SALES BY PRODUCT, 2014 (%)
  • BIOCON
  • FIGURE 47 BIOCON'S SALES BY REGION, 2014 (%)
  • TABLE 47 BIOCON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 48 BIOCON'S SALES BY BUSINESS SEGMENT, 2014 (%)
  • BIOSIDUS
  • BLAUSIEGEL
  • CELON LABS
  • CENTER OF MOLECULAR IMMUNOLOGY
  • CHALVER LABORATORIES
  • CJ HEALTHCARE
  • CLARIS LIFESCIENCES
  • TABLE 48 CLARIS LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • DR. REDDY'S LABORATORIES.
  • FIGURE 49 DR.REDDY'S SALES BY SEGMENT, 2013-2014 (%)
  • TABLE 49 DR. REDDY'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • EMCURE PHARMACEUTICALS
  • HINDUSTAN ANTIBIOTICS
  • HOSPIRA INC.
  • TABLE 50 HOSPIRA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 50 HOSPIRA'S SALES BY REGION, 2014
  • FIGURE 51 HOSPIRA'S SALES BY BUSINESS SEGMENT, 2014 (%)
  • INTAS BIOPHARMACEUTICAL LTD
  • TABLE 51 INTAS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 52 INTAS' SALES BY REGION, 2014 (%)
  • JCR PHARMACEUTICALS CO. LTD.
  • TABLE 52 JCR PHARMACEUTICALS' RECENT FINANCIAL PERFORMANCE, THROUGH 2015 ($ MILLIONS)
  • FIGURE 53 JCR PHARMACEUTICALS' THERAPEUTIC CONTRIBUTION, 2013-2014 (%)
  • JOHNSON & JOHNSON
  • TABLE 53 JOHNSON & JOHNSON'S ERYTHROPOETIN SALES, THROUGH 2014 ($ MILLIONS)
  • FIGURE 54 JOHNSON & JOHNSON'S SALES BY SEGMENT, 2014 (%)
  • TABLE 54 JOHNSON & JOHNSON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • LANDSTEINER SCIENTIFIC S.A. DE C.V.
  • LA RENON HEALTHCARE
  • LG LIFE SCIENCES
  • TABLE 55 LG LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • LUPIN LTD.
  • TABLE 56 LUPIN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 55 LUPIN'S SALES BY REGION, 2014 (%)
  • MEDICE DRUG PUTTER GMBH & CO. KG
  • NOVARTIS INTERNATIONAL AG
  • TABLE 57 NOVARTIS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 56 NOVARTIS' SALES SHARE BY BUSINESS SEGMENTS, 2014 (%)
  • FIGURE 57 NOVARTIS' INTERNATIONAL AG SALES BY REGION, 2014 (%)
  • PANACEA BIOTEC
  • TABLE 58 COMPOSITIONS OF ERYTHROPOIETIN MANUFACTURED BY PANACEA
  • TABLE 59 PANACEA BIOTEC'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 58 PANACEA BIOTEC'S SALES BY REGION, 2014 (%)
  • PROBIOMED
  • RELIANCE LIFE SCIENCES
  • ROCHE
  • TABLE 60 ROCH'S ERYTHROPOETIN SALES BY PRODUCT, THROUGH 2014 ($ MILLIONS)
  • TABLE 61 NEORECORMON/EPOGIN SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 62 MIRCERA SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 63 ROCHE'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • RPG LIFE SCIENCES
  • TABLE 64 RPG LIFESCIENCES RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 59 RPG LIFESCIENCES' SALES BY BUSINESS SEGMENT, 2014 (%)
  • FIGURE 60 RPG LIFESCIENCES' SALES BY REGION, 2014 (%)
  • SERUM INSTITUTE OF INDIA
  • SHANGHAI CHEMO WANBANG BIOPHARMA CO. LTD.
  • SHANTHA BIOTECHNICS
  • STADA ARZNEIMITTEL AG
  • TABLE 65 STADA ARZNEIMITTEL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 61 STADA ARZNEIMITTEL'S THERAPEUTIC CONTRIBUTION, 2014 (%)
  • FIGURE 62 STADA ARZNEIMITTEL'S SALES BY REGION, 2014 ($ MILLIONS)
  • SUN PHARMACEUTICAL INDUSTRIES LTD.
  • TABLE 66 SUN PHARMACEUTICAL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 63 SUN PHARMACEUTICAL'S SALES BY REGION, 2014 (%)
  • FIGURE 64 SUN PHARMACEUTICAL'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • TABLE 67 TEVA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • FIGURE 65 TEVA'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)
  • FIGURE 66 TEVA'S SALES BY REGION, 2014 (%)
  • VHB LIFE SCIENCES LTD.
  • WOCKHARDT LIMITED
  • FIGURE 67 WOCKHARDT'S SALES BY REGION, 2014 (%)
  • TABLE 68 WOCKHARDT'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • ZUVENTUS HEALTH CARE
  • ZYDUS CADILA HEALTHCARE
  • TABLE 69 ZYDUS CADILA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • FIGURE 68 ZYDUS CADILA'S SALES BY REGION, 2014 (%)

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 1 MAJOR EPO R &D DRUG PIPELINE BY TRIAL PHASE
  • TABLE 2 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY CATEGORY, THROUGH 2020 ($ MILLIONS)
  • TABLE 3 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 4 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 5 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, THROUGH 2020 ($ MILLIONS)
  • TABLE 6 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 7 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 8 GLOBAL MARKET FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 9 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 10 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 11 GLOBAL MARKET FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 12 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 13 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 14 GLOBAL MARKET FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 15 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 16 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 17 GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS ONCOLOGY DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 18 GLOBAL MARKET FORECAST FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 19 GLOBAL MARKET FOR EPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 20 GLOBAL MARKET FOR EPOETIN-BETA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 21 GLOBAL MARKET FOR DARBEPOETIN-ALFA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 22 GLOBAL MARKET FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 23 GLOBAL MARKET FOR EPOGEN DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 24 GLOBAL MARKET FOR EPOGEN DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 25 GLOBAL MARKET FOR PROCRIT DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 26 GLOBAL MARKET FOR PROCRIT DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 27 GLOBAL MARKET FOR EPREX DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 28 GLOBAL MARKET FOR EPREX DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 29 GLOBAL MARKET FOR ARANESP DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 30 GLOBAL MARKET FOR ARANESP DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 31 GLOBAL MARKET FOR NEORECORMON DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 32 GLOBAL MARKET FOR NEORECORMON DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 33 GLOBAL MARKET FOR MIRCERA DRUGS BY REGION, THROUGH 2020 ($ MILLIONS)
  • TABLE 34 GLOBAL MARKET FOR MIRCERA DRUGS BY APPLICATION, THROUGH 2020 ($ MILLIONS)
  • TABLE 35 GLOBAL PREVALENCE OF HYPERTENSION BY REGION, 2000-2025 (MILLIONS)
  • TABLE 36 U.S. INCIDENT OF ESRD BASED ON DISEASES, 2011 AND 2012 (MILLIONS)
  • TABLE 37 GLOBAL POPULATION OVER THE AGE OF 60, THROUGH 2020 (MILLIONS)
  • TABLE 38 U.S. INCIDENT OF ESRD BASED ON ETHNICITY, 2011 AND 2012 (MILLIONS)
  • TABLE 39 INCIDENCE OF ANEMIA BY CHEMOTHERAPY AGENTS
  • TABLE 40 GLOBAL ERYTHROPOIETIN BIOLOGIC DRUGS MARKET SHARE BY MANUFACTURER, 2014 (%/$ MILLIONS)
  • TABLE 41 3SBIO'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 42 AMGEN'S ERYTHROPOETIN DRUGS PIPELINE
  • TABLE 43 AMGEN'S ERYTHROPOETIN DRUGS PATENTS
  • TABLE 44 ARANESP'S SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 45 EPOGEN'S SALES BY REGION, 2011-2014 ($ MILLIONS)
  • TABLE 46 AMGEN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 47 BIOCON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 48 CLARIS LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 49 DR. REDDY'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • TABLE 50 HOSPIRA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 51 INTAS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 52 JCR PHARMACEUTICALS' RECENT FINANCIAL PERFORMANCE, THROUGH 2015 ($ MILLIONS)
  • TABLE 53 JOHNSON & JOHNSON'S ERYTHROPOETIN SALES, THROUGH 2014 ($ MILLIONS)
  • TABLE 54 JOHNSON & JOHNSON'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 55 LG LIFESCIENCES' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • TABLE 56 LUPIN'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 57 NOVARTIS' RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 58 COMPOSITIONS OF ERYTHROPOIETIN MANUFACTURED BY PANACEA
  • TABLE 59 PANACEA BIOTEC'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 60 ROCH'S ERYTHROPOETIN SALES BY PRODUCT, THROUGH 2014 ($ MILLIONS)
  • TABLE 61 NEORECORMON/EPOGIN SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 62 MIRCERA SALES BY REGION, THROUGH 2014 ($ MILLIONS)
  • TABLE 63 ROCHE'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 64 RPG LIFESCIENCES RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 65 STADA ARZNEIMITTEL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 66 SUN PHARMACEUTICAL'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 67 TEVA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS/%)
  • TABLE 68 WOCKHARDT'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)
  • TABLE 69 ZYDUS CADILA'S RECENT FINANCIAL PERFORMANCE, THROUGH 2014 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR ERYTHROPOIETIN DRUGS BY TYPE, 2014-2020 ($ MILLIONS)
  • FIGURE 1 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY CATEGORY, 2015 AND 2020 (%)
  • FIGURE 2 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY TYPE, 2015 AND 2020 (%)
  • FIGURE 3 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY TYPE, 2015 AND 2020 (%)
  • FIGURE 4 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY TYPE, 2015 AND 2020 (%)
  • FIGURE 5 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 6 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 7 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 8 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 9 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 10 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN BIOSIMILAR DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 11 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 12 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 13 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DARBEPOETIN-ALFA DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 14 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 15 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR KIDNEY DISEASES BY REGION, 2015 AND 2020 (%)
  • FIGURE 16 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR ONCOLOGY DISEASES BY REGION, 2015 AND 2020 (%)
  • FIGURE 17 GLOBAL MARKET SHARE FOR ERYTHROPOIETIN DRUGS FOR OTHER DISEASES BY REGION, 2015 AND 2020 (%)
  • FIGURE 18 GLOBAL MARKET SHARE FOR EPOETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 19 GLOBAL MARKET SHARE FOR EPOETIN-BETA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 20 GLOBAL MARKET SHARE FOR DARBEPPOIETIN-ALFA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 21 GLOBAL MARKET SHARE FOR OTHER ERYTHROPOIETIN BIOLOGIC DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 22 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 23 GLOBAL MARKET SHARE FOR EPOGEN DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 24 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 25 GLOBAL MARKET SHARE FOR PROCRIT DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 26 GLOBAL MARKET SHARE FOR EPREX DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 27 GLOBAL MARKET SHARE FOR EPREX DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 28 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 29 GLOBAL MARKET SHARE FOR ARANESP DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 30 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 31 GLOBAL MARKET SHARE FOR NEORECORMON DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 32 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY REGION, 2015 AND 2020 (%)
  • FIGURE 33 GLOBAL MARKET SHARE FOR MIRCERA DRUGS BY APPLICATION, 2015 AND 2020 (%)
  • FIGURE 34 NUMBER OF PEOPLE AGES 20 TO 79 WITH DIABETES, BY REGION, 2013 AND 2035 (MILLIONS)
  • FIGURE 35 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES BY TOP TEN COUNTRIES, 2013 (MILLIONS)
  • FIGURE 36 NUMBER OF PEOPLE AGES 20 TO 79, AFFECTED BY DIABETES, BY TOP TEN COUNTRIES, 2035 (MILLIONS)
  • FIGURE 37 NUMBER OF AMERICANS DIAGNOSED WITH DIABETES, 2009-2013 (MILLIONS)
  • FIGURE 38 PREVALENCE OF HYPERTENSION IN PEOPLE AGED ABOVE 25 YEARS BY REGION, 2008 AND 2014
  • FIGURE 39 GLOBAL CANCER PREVALENCE BY TYPE, 2012 (%)
  • FIGURE 40 GLOBAL CANCER PREVALENCE BASED ON FIVE YEAR PERIOD BY TYPE, 2008-2012 (%)
  • FIGURE 41 CANCER PREVALENCE IN MORE DEVELOPED REGIONS BY TYPE, 2012 (%)
  • FIGURE 42 CANCER PREVALENCE BASED ON FIVE YEAR PERIOD IN MORE DEVELOPED REGIONS BY TYPE, 2008-2012 (%)
  • FIGURE 43 CANCER PREVALENCE IN LESS DEVELOPED REGIONS BY TYPE, 2012 (%)
  • FIGURE 44 CANCER PREVALENCE BASED ON FIVE-YEAR PERIOD IN LESS DEVELOPED REGIONS BY TYPE, 2008-2012 (%)
  • FIGURE 45 AMGEN'S REVENUE BY REGION, 2014 (%)
  • FIGURE 46 AMGEN'S SALES BY PRODUCT, 2014 (%)
  • FIGURE 47 BIOCON'S SALES BY REGION, 2014 (%)
  • FIGURE 48 BIOCON'S SALES BY BUSINESS SEGMENT, 2014 (%)
  • FIGURE 49 DR.REDDY'S SALES BY SEGMENT, 2013-2014 (%)
  • FIGURE 50 HOSPIRA'S SALES BY REGION, 2014
  • FIGURE 51 HOSPIRA'S SALES BY BUSINESS SEGMENT, 2014 (%)
  • FIGURE 52 INTAS' SALES BY REGION, 2014 (%)
  • FIGURE 53 JCR PHARMACEUTICALS' THERAPEUTIC CONTRIBUTION, 2013-2014 (%)
  • FIGURE 54 JOHNSON & JOHNSON'S SALES BY SEGMENT, 2014 (%)
  • FIGURE 55 LUPIN'S SALES BY REGION, 2014 (%)
  • FIGURE 56 NOVARTIS' SALES SHARE BY BUSINESS SEGMENTS, 2014 (%)
  • FIGURE 57 NOVARTIS' INTERNATIONAL AG SALES BY REGION, 2014 (%)
  • FIGURE 58 PANACEA BIOTEC'S SALES BY REGION, 2014 (%)
  • FIGURE 59 RPG LIFESCIENCES' SALES BY BUSINESS SEGMENT, 2014 (%)
  • FIGURE 60 RPG LIFESCIENCES' SALES BY REGION, 2014 (%)
  • FIGURE 61 STADA ARZNEIMITTEL'S THERAPEUTIC CONTRIBUTION, 2014 (%)
  • FIGURE 62 STADA ARZNEIMITTEL'S SALES BY REGION, 2014 ($ MILLIONS)
  • FIGURE 63 SUN PHARMACEUTICAL'S SALES BY REGION, 2014 (%)
  • FIGURE 64 SUN PHARMACEUTICAL'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)
  • FIGURE 65 TEVA'S THERAPEUTIC CONTRIBUTION BY SEGMENT, 2014 (%)
  • FIGURE 66 TEVA'S SALES BY REGION, 2014 (%)
  • FIGURE 67 WOCKHARDT'S SALES BY REGION, 2014 (%)
  • FIGURE 68 ZYDUS CADILA'S SALES BY REGION, 2014 (%)
Back to Top